Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 306.58M P/E - EPS this Y -15.40% Ern Qtrly Grth -
Income -135.38M Forward P/E -2.79 EPS next Y 51.10% 50D Avg Chg -2.00%
Sales 4.39M PEG -0.85 EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 1.66 EPS next 5Y 2.40% 52W High Chg -59.00%
Recommedations 2.20 Quick Ratio 0.88 Shares Outstanding 292.64M 52W Low Chg 48.00%
Insider Own 10.18% ROA -42.32% Shares Float 117.76M Beta 1.66
Inst Own 62.30% ROE -129.32% Shares Shorted/Prior 14.39M/13.12M Price 1.20
Gross Margin - Profit Margin - Avg. Volume 1,214,056 Target Price 6.00
Oper. Margin -3,667.50% Earnings Date Nov 7 Volume 1,042,734 Change -6.98%
About Precigen, Inc.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Precigen, Inc. News
11/20/24 Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%
11/14/24 Precigen Reports Third Quarter 2024 Financial Results and Business Updates
11/12/24 Precigen to Participate in the Stifel 2024 Healthcare Conference
09:04 AM High Growth Tech Stocks To Watch In October 2024
09/16/24 Precigen to Participate in the 2024 Cantor Global Healthcare Conference
09/12/24 While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 43% ownership
08/16/24 Precigen Second Quarter 2024 Earnings: Misses Expectations
08/14/24 Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
08/09/24 Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
08/07/24 Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
08/06/24 Precigen Announces Proposed $30 Million Public Offering of Common Stock
08/06/24 Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
07/31/24 Precigen, Inc.'s (NASDAQ:PGEN) Shift From Loss To Profit
07/23/24 Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
07/14/24 Precigen Insiders Added US$1.72m Of Stock To Their Holdings
06/26/24 Is Precigen (NASDAQ:PGEN) In A Good Position To Invest In Growth?
06/04/24 Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years
06/03/24 Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
05/23/24 Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
05/14/24 Precigen Reports First Quarter 2024 Financial Results and Business Updates
PGEN Chatroom

User Image Article_AI Posted - 1 day ago

$PGEN Precigen Reports Q3 2024 Financial Results Precigen, Inc. ( ($PGEN) ) has released its Q3 earnings. Here is a breakdown of the information Precigen, Inc. presented to its investors. Precigen... https://www.stck.pro/news/PGEN/93953507/

User Image ASTAD13 Posted - 2 days ago

$PGEN anything under $1 is a stupid discount

User Image ASTAD13 Posted - 2 days ago

$PGEN nobody in their right mind is selling right now. Buy and hold til the big news breaks out.

User Image ASTAD13 Posted - 3 days ago

$PGEN touch .90 today please

User Image ASTAD13 Posted - 3 days ago

$PGEN 4 cents a day will keep the trolls away

User Image ASTAD13 Posted - 4 days ago

$PGEN hold the line and keep adding if you can. Big things ahead

User Image Arbitrage7 Posted - 4 days ago

$PGEN This turd needs a double flush! POS going down 25 cents

User Image ASTAD13 Posted - 5 days ago

$PGEN be on the right side of the fence the day the approval goes through. Multi billion dollar market cap in the near future.

User Image ASTAD13 Posted - 5 days ago

$PGEN highly recommend blocking the 3 sad trolls who spend more time on this feed than they do outside.

User Image ASTAD13 Posted - 5 days ago

$PGEN hopefully the idiots selling this are out and this is the rock bottom.

User Image Arbitrage7 Posted - 5 days ago

$PGEN This POS is getting closer to 25 cents! It won’t be long… New lower lows…

User Image forgottenchuck Posted - 5 days ago

$PGEN kennedy is anti vaccine, what are the chances that prgn-2012 gets approval. kennedy will be in charge of health and human resources when it comes up for approval. does it get approval

User Image Persevere_With_Patience Posted - 1 week ago

$PGEN is a sleeper IMO, their RRP therapy is life changing for patients and has a high likelihood of get BLA approval by mid-next year and has blockbuster potential. At $230 MC and high management ownership, I see this as an asymmetrical opportunity for upside. Also price does not reflect their oncology pipeline either.

User Image Persevere_With_Patience Posted - 1 week ago

@Herr_Chicken Hey Herr! $PGEN is a sleeper IMO, their RRP therapy is life changing for patients and has a high likelihood of get BLA approval by mid-next year and has blockbuster potential. At $230 MC and high management ownership, I see this as an asymmetrical opportunity for upside. Can't wait to hear your feedback. Thx!

User Image 809capital Posted - 1 week ago

$PGEN lol 0.03 from target to buy and sell right fucking away.

User Image Wacousta Posted - 1 week ago

$PGEN 45 days and counting 10q link https://investors.precigen.com/node/14071/html

User Image Wacousta Posted - 1 week ago

$PGEN Oh by the way. Our 3rd quarter 2024 report. https://investors.precigen.com/node/14061/pdf

User Image lecorb Posted - 1 week ago

$PGEN Precigen GAAP EPS of -$0.09 misses by $0.01, revenue of $0.95M misses by $0.33M

User Image d_risk Posted - 1 week ago

$PGEN - Precigen Inc. Common Stock - 10Q - Updated Risk Factors Shift from strategic prioritization risks to Nasdaq listing compliance risks; delisting threat impacts stock price and future financing. #Risk https://d-risk.ai/PGEN/10-Q/2024-11-14

User Image rubraquercus Posted - 1 week ago

$PGEN Experienced folks are not afraid of selling for the tax loss...6 more weeks of this at least

User Image rubraquercus Posted - 1 week ago

$PGEN did ya?

User Image rubraquercus Posted - 1 week ago

$PGEN poor hell-in and kirkiefuk, just can't get off the ground

User Image AnalyticalOne Posted - 1 week ago

$PGEN I guess we're looking at the Phoenix Rising😏

User Image MALO_MY_BOY Posted - 1 week ago

$PGEN

User Image MALO_MY_BOY Posted - 1 week ago

@809capital Hey Sport! Do you still have that limit order in to buy 50,000 $PGEN @ .75 per share?

User Image rubraquercus Posted - 1 week ago

$PGEN the pigeon is dead...

User Image rubraquercus Posted - 2 weeks ago

$KRYS Thank you for leaving kirkiefuk at $PGEN

User Image rubraquercus Posted - 2 weeks ago

$PGEN permabulls out in full force when they think the TAM of the only hope they have is going to be a multi billion dollar drug. Assuming it even gets approved. It is their last hope, yours too...

User Image Golfer109 Posted - 2 weeks ago

$PGEN well the truth of the matter is the CEO and chairman of the board or whatever his name is you know who he is it's a crook he cooked 25,000 shares at a dollar 75 and another 22 million shares at 85 cents that was his crooking now he's ready to let it go cuz he owns over 80% and he's going to just move it and everybody that lost by selling they are sure cooking if you could hold on to his nonsense and come to the Final Act you're going to be really well well we're final Act is about to come good luck all you that have suffered like I have

User Image Golfer109 Posted - 2 weeks ago

$PGEN couldn't have said it better

Analyst Ratings
JMP Securities Market Outperform Aug 15, 24
HC Wainwright & Co. Buy Aug 15, 24
JMP Securities Market Outperform Jun 4, 24
Stifel Buy Jun 3, 24
HC Wainwright & Co. Buy Jun 3, 24
Cantor Fitzgerald Overweight May 15, 24
Stifel Buy May 15, 24
HC Wainwright & Co. Buy May 15, 24
JP Morgan Underweight Mar 22, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KIRK RANDAL J Director Director Dec 28 Buy 1.41 96,686 136,327 1,096,686 12/29/23
KINDLER JEFFREY B Director Director Dec 28 Sell 1.41 96,686 136,327 238,275 12/29/23
Sabzevari Helen President and CEO President and CEO Aug 23 Sell 1.53 76,969 117,763 1,560,004 08/25/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 23 Sell 1.64 10,947 17,953 428,916 08/25/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 23 Sell 1.64 5,388 8,836 133,474 08/25/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 23 Sell 1.64 8,891 14,581 458,903 08/25/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 23 Sell 1.64 9,045 14,834 161,051 08/25/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 16 Sell 1.55 8,741 13,549 448,916 08/18/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 16 Sell 1.55 8,893 13,784 152,162 08/18/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 16 Sell 1.55 10,762 16,681 418,153 08/18/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 16 Sell 1.55 5,298 8,212 123,382 08/18/23
Sabzevari Helen President and CEO President and CEO Aug 16 Sell 1.66 55,855 92,719 1,495,386 08/18/23
KIRK RANDAL J Director Director Aug 15 Buy 1.52 500,000 760,000 31,837,786 08/17/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 09 Sell 1.21 5,429 6,569 113,200 08/11/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 09 Sell 1.21 11,026 13,341 407,205 08/11/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 09 Sell 1.21 6,852 8,291 143,121 08/11/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 09 Sell 1.21 8,956 10,837 438,779 08/11/23
Sabzevari Helen President and CEO President and CEO Aug 09 Sell 1.44 41,436 59,668 1,409,654 08/11/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Aug 02 Sell 1.2 8,789 10,547 428,857 08/04/23
Lehr Donald P. Chief Legal Officer Chief Legal Officer Aug 02 Sell 1.2 10,821 12,985 396,521 08/04/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 02 Sell 1.2 6,724 8,069 132,039 08/04/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Aug 02 Sell 1.2 5,328 6,394 103,149 08/04/23
Sabzevari Helen President and CEO President and CEO Aug 02 Sell 1.1 52,870 58,157 1,309,503 08/04/23
Shah Rutul R Chief Operating Offi.. Chief Operating Officer Jan 27 Buy 1.75 9,142 15,998 62,037 01/30/23
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs Jan 27 Buy 1.75 28,571 49,999 381,012 01/30/23
Sabzevari Helen President and CEO President and CEO Jan 27 Buy 1.75 22,857 40,000 937,613 01/30/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Jan 27 Buy 1.75 28,571 49,999 84,961 01/30/23
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer Aug 23 Buy 2.09 24,500 51,205 56,390 08/24/22
KINDLER JEFFREY B Director Director Aug 11 Sell 2.30 50,000 115,000 214,411 08/15/22
Perez Jeffrey Thomas SVP, IP Affairs SVP, IP Affairs May 16 Sell 1.28 14,778 18,916 333,502 05/18/22
Thomasian Harry Jr. Chief Financial Offi.. Chief Financial Officer May 16 Sell 1.28 2,719 3,480 31,890 05/18/22
Lehr Donald P. Chief Legal Officer Chief Legal Officer May 16 Sell 1.28 18,196 23,291 323,274 05/18/22
Sabzevari Helen President and CEO President and CEO May 12 Sell 1.19 177,968 211,782 897,091 05/16/22
KIRK RANDAL J Director Director Nov 19 Buy 3.61 1,000,000 3,610,000 1,000,000 11/23/21
Ares Trading S.A. 10% Owner 10% Owner Oct 12 Sell 4.64 143,796 667,213 20,647,152 10/14/21
Ares Trading S.A. 10% Owner 10% Owner Oct 08 Sell 4.68 116,204 543,835 20,790,948 10/12/21
Ares Trading S.A. 10% Owner 10% Owner Oct 06 Sell 4.86 113,100 549,666 20,907,152 10/08/21
Ares Trading S.A. 10% Owner 10% Owner Aug 26 Sell 5.83 78,607 458,279 21,870,152 08/26/21